Omeros shares are trading higher after the FDA approved YARTEMLEA to treat hematopoietic stem cell transplant–associated thrombotic microangiopathy.

Omeros Corporation -4.27% Post

Omeros Corporation

OMER

11.42

11.43

-4.27%

+0.09% Post
Omeros shares are trading higher after the FDA approved YARTEMLEA to treat hematopoietic stem cell transplant–associated thrombotic microangiopathy.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via